Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Nat Med
    July 2024
  1. FORTEA J, Vaque-Alcazar L, Pegueroles J, Alcolea D, et al
    Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03159.
    >> Share

  2. PAPPALETTERA C, Carrarini C, Cappa S, Caraglia N, et al
    Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03158.
    >> Share

  3. ROSENZWEIG N, Kleemann KL, Rust T, Carpenter M, et al
    Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
    Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03122.
    >> Share

    June 2024
  4. JACK CR JR, Andrews SJ, Beach TG, Buracchio T, et al
    Revised criteria for the diagnosis and staging of Alzheimer's disease.
    Nat Med. 2024 Jun 28. doi: 10.1038/s41591-024-02988.
    >> Share

  5. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 Jun 17. doi: 10.1038/s41591-024-03127.
    >> Share

    May 2024
  6. SHANKS HRC, Chen K, Reiman EM, Blennow K, et al
    p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
    Nat Med. 2024 May 17. doi: 10.1038/s41591-024-02977.
    >> Share

  7. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02931.
    >> Share

  8. XU Q, Liang Z, Huang Y
    APOE4 homozygosity is a new genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02923.
    >> Share

    March 2024
  9. O'LEARY K
    A timeline of biomarker changes before Alzheimer's disease.
    Nat Med. 2024 Mar 15. doi: 10.1038/d41591-024-00018.
    >> Share

    February 2024
  10. BARTHELEMY NR, Salvado G, Schindler S, He Y, et al
    Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests.
    Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869.
    >> Share

    January 2024
  11. JUCKER M, Walker LC
    Evidence for iatrogenic transmission of Alzheimer's disease.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02768.
    >> Share

  12. BANERJEE G, Farmer SF, Hyare H, Jaunmuktane Z, et al
    Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02729.
    >> Share

  13. O'LEARY K
    Modeling real-world data to repurpose drugs for Alzheimer's disease.
    Nat Med. 2024 Jan 18. doi: 10.1038/d41591-024-00003.
    >> Share

    December 2023
  14. O'LEARY K
    Positive results in Alzheimer's disease trials.
    Nat Med. 2023;29:2973.
    >> Share

    November 2023
  15. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Author Correction: Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Nov 20. doi: 10.1038/s41591-023-02718.
    >> Share

    October 2023
  16. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02639.
    >> Share

    September 2023
  17. LONGO FM, Massa SM
    Senolytic therapy for Alzheimer's disease.
    Nat Med. 2023 Sep 27. doi: 10.1038/s41591-023-02541.
    >> Share

  18. GONZALES MM, Garbarino VR, Kautz TF, Palavicini JP, et al
    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
    Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02543.
    >> Share

  19. SELF WK, Holtzman DM
    Emerging diagnostics and therapeutics for Alzheimer disease.
    Nat Med. 2023 Sep 4. doi: 10.1038/s41591-023-02505.
    >> Share

    August 2023

  20. Events in the brain during the evolution of Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02477.
    >> Share

  21. JOHNSON ECB, Bian S, Haque RU, Carter EK, et al
    Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02476.
    >> Share


  22. A fluid biomarker accurately detects tau aggregate pathology in Alzheimer's disease.
    Nat Med. 2023 Aug 2. doi: 10.1038/s41591-023-02468.
    >> Share

  23. PALMQVIST S, Rossi M, Hall S, Quadalti C, et al
    Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
    Nat Med. 2023;29:1971-1978.
    >> Share

  24. QUADALTI C, Palmqvist S, Hall S, Rossi M, et al
    Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Nat Med. 2023;29:1964-1970.
    >> Share

    July 2023
  25. O'LEARY K
    Putting the brakes on Alzheimer's disease.
    Nat Med. 2023 Jul 31. doi: 10.1038/d41591-023-00067.
    >> Share

  26. HORIE K, Salvado G, Barthelemy NR, Janelidze S, et al
    CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Nat Med. 2023 Jul 13. doi: 10.1038/s41591-023-02443.
    >> Share

  27. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Jul 4. doi: 10.1038/s41591-023-02406.
    >> Share

    June 2023
  28. BOUZID H, Belk JA, Jan M, Qi Y, et al
    Clonal hematopoiesis is associated with protection from Alzheimer's disease.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02397.
    >> Share

    May 2023
  29. BELLAVER B, Povala G, Ferreira PCL, Ferrari-Souza JP, et al
    Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease.
    Nat Med. 2023 May 29. doi: 10.1038/s41591-023-02380.
    >> Share

  30. LJUBENKOV PA, Rabinovici GD
    Silencing tau to treat early Alzheimer's disease.
    Nat Med. 2023 May 17. doi: 10.1038/s41591-023-02357.
    >> Share

  31. LOPERA F, Marino C, Chandrahas AS, O'Hare M, et al
    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
    Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02318.
    >> Share

    April 2023
  32. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Apr 24. doi: 10.1038/s41591-023-02326.
    >> Share

    December 2022
  33. ASHTON NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, et al
    Differential roles of Abeta42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring.
    Nat Med. 2022 Dec 1. doi: 10.1038/s41591-022-02074.
    >> Share

  34. HORIE K, Barthelemy NR, Spina S, VandeVrede L, et al
    CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.
    Nat Med. 2022;28:2547-2554.
    >> Share

    November 2022
  35. MOUTINHO S
    The long road to a cure for Alzheimer's disease is paved with failures.
    Nat Med. 2022;28:2228-2231.
    >> Share

  36. OSSENKOPPELE R, Pichet Binette A, Groot C, Smith R, et al
    Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
    Nat Med. 2022;28:2381-2387.
    >> Share


  37. Amyloid-beta and tau PET scans predict clinical progression in cognitively unimpaired people.
    Nat Med. 2022;28:2267-2268.
    >> Share

    September 2022

  38. Toward inflammation-free therapeutics in Alzheimer's disease.
    Nat Med. 2022 Sep 8. pii: 10.1038/s41591-022-01972.
    >> Share

  39. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022;28:1965.
    >> Share

  40. JUNG H, Lee SY, Lim S, Choi HR, et al
    Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein.
    Nat Med. 2022;28:1802-1812.
    >> Share

    August 2022
  41. MILA-ALOMA M, Ashton NJ, Shekari M, Salvado G, et al
    Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease.
    Nat Med. 2022 Aug 11. pii: 10.1038/s41591-022-01925.
    >> Share

    July 2022
  42. SCHINDLER SE, Karikari TK
    Comorbidities confound Alzheimer's blood tests.
    Nat Med. 2022 Jul 4. pii: 10.1038/s41591-022-01875.
    >> Share

  43. MIELKE MM, Dage JL, Frank RD, Algeciras-Schimnich A, et al
    Performance of plasma phosphorylated tau 181 and 217 in the community.
    Nat Med. 2022;28:1398-1405.
    >> Share

    February 2022
  44. O'LEARY K
    Mapping the mediators of Alzheimer's disease.
    Nat Med. 2022 Feb 28. pii: 10.1038/d41591-022-00037.
    >> Share

    September 2021
  45. PASCOAL TA, Benedet AL, Ashton NJ, Kang MS, et al
    Microglial activation and tau propagate jointly across Braak stages.
    Nat Med. 2021;27:1592-1599.
    >> Share

  46. PERLMUTTER JS
    Aducanumab: look before leaping.
    Nat Med. 2021;27:1499.
    >> Share

  47. CUMMINGS J
    Why aducanumab is important.
    Nat Med. 2021;27:1498.
    >> Share

    August 2021
  48. JABBARI E, Duff KE
    Tau-targeting antibody therapies: too late, wrong epitope or wrong target?
    Nat Med. 2021;27:1341-1342.
    >> Share

    July 2021
  49. RABINOVICI GD
    Dominantly inherited Alzheimer's disease: a compass for drug development.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01434.
    >> Share

    June 2021
  50. SALLOWAY S, Farlow M, McDade E, Clifford DB, et al
    A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Nat Med. 2021 Jun 21. pii: 10.1038/s41591-021-01369.
    >> Share

  51. HANSSON O
    Biomarkers for neurodegenerative diseases.
    Nat Med. 2021;27:954-963.
    >> Share

    May 2021
  52. PALMQVIST S, Tideman P, Cullen N, Zetterberg H, et al
    Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Nat Med. 2021 May 24. pii: 10.1038/s41591-021-01348.
    >> Share

    April 2021
  53. VOGEL JW, Young AL, Oxtoby NP, Smith R, et al
    Four distinct trajectories of tau deposition identified in Alzheimer's disease.
    Nat Med. 2021 Apr 29. pii: 10.1038/s41591-021-01309.
    >> Share

    January 2021
  54. DUJARDIN S, Commins C, Lathuiliere A, Beerepoot P, et al
    Author Correction: Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01251.
    >> Share

    November 2020
  55. ARNOLD C
    Post-hoc analysis could give new life to the Alzheimer's drug aducanumab.
    Nat Med. 2020 Nov 2. pii: 10.1038/d41591-020-00031.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016